Back to search results
NCT06790498

Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product

Enrolling by Invitation
Not specifiedAges 30–80Observational
Prokidney
~50 participants
Updated 2026-09-17 on ClinicalTrials.gov
What's tested:Renal Autologous Cell Therapy (REACT)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-term safety of REACT follow-up after completing their enrollment in the investigational clinical studies.
Measured over 60 months from completion of parent protocol EOS Visit

Conditions

Diabetic Kidney Disease
Chronic Kidney Disease

Explore related trials

Chronic Kidney DiseaseDiabetic Nephropathy

NCT06790498

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Boise Kidney & Hypertension Institute

    Meridian, Idahono site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Study Director · STUDY_DIRECTOR · Prokidney

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The participant must have received REACT in a previous trial (REGEN-006, REGEN- 007, and REGEN-015) for the treatment of chronic kidney disease and completed an end of study visit in their previous trial per protocol.
The participant is willing and able to cooperate with all aspects of the protocol.
The participant is willing and able to provide signed informed consent.

What this trial measures

  • Long-term safety of REACT follow-up after completing their enrollment in the investigational clinical studies.60 months from completion of parent protocol EOS Visit

    Evaluation of the long-term safety of REACT will be assessed via: * Incidence of delayed serious adverse events (SAEs) obtained throughout long-term follow-up after completing their enrollment in the investigational clinical studies. * Incidence of delayed biopsy-related SAEs obtained throughout long-term follow-up after completing their enrollment in the investigational clinical studies. * Incidence of delayed injection procedure related SAEs obtained throughout long-term follow-up after completing their enrollment in the investigational clinical studies. * Incidence of delayed investigational product related SAEs obtained throughout long-term follow-up after completing their enrollment in the investigational clinical studies.